Safety and Pharmacokinetics of Intranasally Administered Heparin Safety and Pharmacokinetics of Intranasally Administered Heparin

• Published in: Pharmaceutical research Vol. 39; no. 3; pp. 541 - 551
• Main Authors: Harris, Hannah M., Boyet, Katherine L., Liu, Hao, Dwivedi, Rohini, Ashpole, Nicole M., Tandon, Ritesh, Bidwell, Gene L., Cheng, Zhi, Fassero, Lauren A., Yu, Christian S., Pomin, Vitor H., Mitra, Dipanwita, Harrison, Kerri A., Dahl, Eric, Gurley, Bill J., Kotha, Arun Kumar, Chougule, Mahavir Bhupal, Sharp, Joshua S.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2022; Springer; Springer Nature B.V
• Subjects: Adverse events; Animals; Anticoagulants; Anticoagulants - adverse effects; Background levels; Biochemistry; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Blood; Blood coagulation; COVID-19; Dosage; Heparin; Human subjects; Humans; Medical examination; Medical Law; Mice; Mice, Inbred C57BL; Nose; Partial Thromboplastin Time; Pharmacokinetics; Pharmacology/Toxicology; Pharmacy; Platelets; Polysaccharides; Research Paper; Safety; Safety and security measures; Sulfates; Thromboplastin; Toxicity; heparin; intranasal delivery; SARS-CoV-2; Covid-19

Purpose Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity. Method...